Trial · NCT02394730
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Percent Change From Baseline for D-dimer (ng/mL) to the Average of Weeks 8 and 12 | at week 8 and week 12 | Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transforming the log10 difference to obtain percentage change from baseline. |
| Secondary | Number of Participants in Each Treatment Group With Plasma HIV-1 RNA <50 Copies/mL | at week 18 | Number of participants in each treatment group with plasma HIV-1 RNA \<50 copies/mL at week 18 |
| Secondary | Mean Change From Baseline to Week 12 in CD4+ Cell Counts | at week 12 | Mean of week 12 CD4+ cell count minus mean of week 0 CD4+ cell count |
| Secondary | Mean Change From Baseline to Week 12 in CD8+ Cell Counts | at week 12 | Mean of week 12 CD8+ cell count minus mean of week 0 CD4+ cell count |
| Secondary | Number of Patients in Each Treatment Group With D-dimer <165ng/mL at Week 12 | week 12 | Number of patients in each treatment group with d-dimer \<165ng/mL at week 12 |
| Secondary | Number of Patients in Each Treatment Group With D-dimer > or Equal to 165ng/mL at Week 18 | week 18 | Number of patients in each treatment group with d-dimer \> or equal to 165ng/mL at week 18 |
| Secondary | Mean Change From Baseline in log10 D-Dimer | at week 18 | Differences between treatment groups in mean change from week 0 log10 d-dimer to week 18 |
| Secondary | Mean Change From Baseline in log10 Hs-CRP at Week 18 | at week 18 | Differences between treatment groups in mean change from baseline log10 hs-CRP to week 18. ie Week 18 log10 hs-CRP minus week 0 log10 hs-CRP |
| Secondary | Percent Change From Baseline Hs-CRP (ug/mL) to the Average of Week 8 and Week 12 | week 8 and 12 | Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transformed the log10 difference to obtain percentage change from baseline. |
| Secondary | Mean Percent Change From Baseline IL-6 (pg/mL) to the Average of Week 8 and Week 12 | at week 8 and week 12 | Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transformed the log10 difference to obtain percentage change from baseline. |
| Secondary | Differences Between Treatment Groups in Mean Change From Baseline log10 IL-6 | at week 18 | Differences between treatment groups in mean change from baseline log10 IL-6 at week 18 |
| Secondary | Total Number of Participants With BARC Type 1, 2, 3, 4, or 5 Bleeding Episodes | at week 18 | Bleeding Academic Research Consortium (BARC) Definitions for Bleeding Events Type 1 -bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional Type 2 - overt, actionable sign of haemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a healthcare professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation Type 3- Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid) Type 4 - Coronary Artery Bypass Graft procedure-related bleeding Type 5 - |
| Secondary | Total Number of Participants With Any SAE Between Baseline and Week 18 | week 18 | Total number of participants with any SAE between baseline and week 18 |
| Secondary | Total Number of Participants With Any AE Between Baseline to Week 18 | week 18 | Total number of participants with any AE between week 0 to week 18 |
| Secondary | Changes From Baseline in Renal Function Measured by the CKD-EPI Estimate of Creatinine Clearance at Week 12 | at week 12 | Changes from baseline in renal function measured by the CKD-EPI estimate of creatinine clearance at week 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02394730/registered